SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Do Important Drugs Reach the Market Sooner?
3 references·16 citing·45 second hop
Do Important Drugs Reach the Market Sooner? (1994)Do Important Drugs Reach the Market Soone…Cost of innovation in the pharmaceutical industry (1991)Cost of innovation in the pha…A New Look at the Returns and Risks to Pharmaceutical R&D (1990)A New Look at the Returns and…An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments (1973)An Evaluation of Consumer Pro…Technological leapfrogging and country strategic patent policy (2022)Technological leapfrogging an…Global norm of national treatment for patent uncertainties: A longitudinal comparison between the US and China (2017)Global norm of national treat…Regional Dynamics of Innovation: Investigating the Co-evolution of Patents, Research and Development (R&D), and Employment (2010)Regional Dynamics of Innovati…Retail price regulation and innovation: Reference pricing in the pharmaceutical industry (2009)Retail price regulation and i…Research Choice and Finance in University Bioscience (2009)Research Choice and Finance i…Regulatory Errors with Endogenous Agendas (2007)Regulatory Errors with Endoge…Are More Important Patents Approved More Slowly and Should They Be (2007)Are More Important Patents Ap…Anti-depressants and Suicide (2007)Anti-depressants and SuicideThe role of firm characteristics in pharmaceutical product launches (2006)The role of firm characterist…The Quantity And Quality Of Worldwide New Drug Introductions, 1982–2003 (2006)The Quantity And Quality Of W…Market response to FDA announcements (2006)Market response to FDA announ…Is the Pharmaceutical Industry in a Productivity Crisis? (2006)Is the Pharmaceutical Industr…Sources of Bureaucratic Delay: A Case Study of FERC Dam Relicensing (2005)Sources of Bureaucratic Delay…Patents, Price Controls, and Access to New Drugs: How Policy Affects Global Market Entry (2005)Patents, Price Controls, and …New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms (2000)New Drug Innovation and Pharm…The Economic Side Effects of Dangerous Drug Announcements (1994)The Economic Side Effects of …Measuring Competence? Exploring Firm Effects in Pharmaceutical Research (1994)Can Patents Deter Innovation? The Anticommons in Biomedical Research (1998)Can the pharmaceutical industry reduce attrition rates? (2004)Many are called, few are chosen: the role of science in drug development decisions (2023)Increasing Returns and Long-Run Growth (1986)The Competitive Advantage of Nations (1990)The Competitive Advantage of Nations (1991)TECHNOLOGICAL INNOVATION AND EMPLOYMENT IN DERIVED LABOUR DEMAND MODELS: A HIERARCHICAL META‐REGRESSION ANALYSIS (2017)Does Regulation Drive Out Competition in Pharmaceutical Markets? (2000)Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price (2002)The price of innovation: new estimates of drug development costs (2003)Follow-on biologics: data exclusivity and the balance between innovation and competition (2008)Pharmaceutical Pricing Policies in a Global Market (2008)Measuring the efficiency of large pharmaceutical companies: an industry analysis (2016)Industrial Market Structure and Economic Performance. (1971)An Evolutionary Theory of Economic Change (1983)An Evolutionary Theory of Economic Change. (1983)Innovation and Marketing in the Pharmaceutical Industry (2013)Dynamic impact of uncertainty on R&D cooperation formation and research performance: Evidence from the bio-pharmaceutical industry (2017)MONOPOLISTIC COMPETITION AND OPTIMUM PRODUCT DIVERSITY (1975)Entry and Competition in Concentrated Markets (1991)The Regulation of Entry (2000)Effects of Regulation on Drug Launch and Pricing in Interdependent Markets (2012)Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents (2003)The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)Pharmaceutical Price Controls and Entry Strategies (2007)Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes (2009)Determinants of branded prescription medicine prices in OECD countries (2011)What is the impact of intellectual property rules on access to medicines? A systematic review (2022)Conditional logit analysis of qualitative choice behavior (1972)Qualitative Response Models: A Survey (1994)Sources and Financial Consequences of Radical Innovation: Insights from Pharmaceuticals (2003)The cost of biopharmaceutical R&D: is biotech different? (2007)Essential medicines for universal health coverage (2016)Prospect Theory: An Analysis of Decision under Risk (1979)Prospect theory: An analysis of decision under risk (1988)Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication (2005)THE IMPACT OF MENTAL HEALTH INSURANCE LAWS ON STATE SUICIDE RATES (2011)Depressive disorders in childhood and adolescence (2015)Income Shocks and Suicides: Causal Evidence From Indonesia (2018)The Transitional Gains Trap (1975)The machinery of freedom: guide to a radical capitalism (1990)Innovative productivity and returns to scale in the pharmaceutical industry (1993)Pricing, Profits, and Technological Progress in the Pharmaceutical Industry (1993)Returns to R&D on new drug introductions in the 1980s (1994)
this work references cited by second hop

References

  • 1991Cost of innovation in the pharmaceutical industry763 cited
  • 1973An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments369 cited
  • 1990A New Look at the Returns and Risks to Pharmaceutical R&D286 cited

Cited by

  • 2007Anti-depressants and Suicide119 cited
  • 2006The role of firm characteristics in pharmaceutical product launches105 cited
  • 2006The Quantity And Quality Of Worldwide New Drug Introductions, 1982–2003103 cited
  • 2005Patents, Price Controls, and Access to New Drugs: How Policy Affects Global Market Entry92 cited
  • 2010Regional Dynamics of Innovation: Investigating the Co-evolution of Patents, Research and Development (R&D), and Employment88 cited
  • 2000New Drug Innovation and Pharmaceutical Industry Structure: Trends in the Output of Pharmaceutical Firms78 cited
  • 2006Is the Pharmaceutical Industry in a Productivity Crisis?77 cited
  • 2009Retail price regulation and innovation: Reference pricing in the pharmaceutical industry71 cited
  • 1994The Economic Side Effects of Dangerous Drug Announcements70 cited
  • 2007Regulatory Errors with Endogenous Agendas57 cited
  • 2005Sources of Bureaucratic Delay: A Case Study of FERC Dam Relicensing54 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

2006
Market response to FDA announcements
27 cited
  • 2007Are More Important Patents Approved More Slowly and Should They Be23 cited
  • 2009Research Choice and Finance in University Bioscience18 cited
  • 2017Global norm of national treatment for patent uncertainties: A longitudinal comparison between the US and China16 cited
  • 2022Technological leapfrogging and country strategic patent policy9 cited